---
document_datetime: 2025-12-02 04:50:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro.html
document_name: gazyvaro.html
version: success
processing_time: 0.1197341
conversion_datetime: 2025-12-24 22:47:49.979235
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Gazyvaro

[RSS](/en/individual-human-medicine.xml/66305)

##### Authorised

This medicine is authorised for use in the European Union

obinutuzumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Gazyvaro](#news-on)
- [Related content](#related-content-660)
- [More information on Gazyvaro](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Gazyvaro is a cancer medicine used to treat adults with:

- previously untreated chronic lymphocytic leukaemia (CLL). CLL is a cancer of B-lymphocytes, a type of white blood cell. Gazyvaro is used together with chlorambucil (another cancer medicine) in patients for whom the cancer medicine fludarabine is not recommended;
- follicular lymphoma (FL), another type of cancer of B-lymphocytes. Gazyvaro is used together with chemotherapy (other cancer medicines) in patients who have not had previous treatment for advanced FL. It is also used with the medicine bendamustine in patients whose disease has not responded to treatment involving the medicine rituximab or whose cancer has progressed within 6 months after such treatment. Once the disease has responded to treatment, Gazyvaro is then used on its own for the maintenance treatment of FL.

Gazyvaro contains the active substance obinutuzumab.

These diseases are rare, and Gazyvaro was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency's website (CLL: [10 October 2012](/en/medicines/human/orphan-designations/eu-3-12-1054) ;  FL: [19 June 2015](/en/medicines/human/orphan-designations/eu-3-15-1504) ).

Expand section

Collapse section

## How is Gazyvaro used?

Gazyvaro can only be obtained with a prescription and treatment should be given under the close supervision of an experienced doctor. As serious side effects including allergic reactions can develop, treatment should be given in facilities where these reactions can be treated promptly.

Gazyvaro is given by infusion (drip) into a vein over several hours. It is given in six or eight cycles and each cycle lasts 21 or 28 days.

The dosage schedule depends on what Gazyvaro is used for.

Patients may also be given other medicines to prevent infusion-related reactions and other side effects. For more information about using Gazyvaro, see the package leaflet or contact your doctor or pharmacist.

## How does Gazyvaro work?

The active substance in Gazyvaro, obinutuzumab, is a monoclonal antibody (a type of protein) that has been designed to attach to the protein CD20, which is found on B-lymphocytes. In CLL and FL, cancerous B-lymphocytes multiply too quickly and replace normal cells in the bone marrow (where blood cells are made) and in lymph nodes. By attaching to CD20 on B-lymphocytes, obinutuzumab makes them a target for the body's immune (defence) system, which kills the B-lymphocytes.

## What benefits of Gazyvaro have been shown in studies?

CLL

In CLL, Gazyvaro delayed the disease getting worse in previously untreated patients who had other medical conditions and were therefore ineligible for fludarabine-based therapy. In one main study involving 781 patients, those treated with Gazyvaro and chlorambucil lived longer without their disease getting worse than patients treated with chlorambucil alone (26.7 months on average versus 11.1 months). Similarly, patients treated with Gazyvaro and chlorambucil lived longer without their disease getting worse than patients treated with rituximab and chlorambucil (26.7 months versus 15.2 months).

FL

Gazyvaro was of benefit in one main study involving 1,202 patients with previously untreated FL. The study compared Gazyvaro plus other chemotherapy medicines with rituximab plus other chemotherapy medicines. Over a follow-up period of about 3 years on average, 17% (101 of 601 patients) given Gazyvaro died or their disease got worse, compared with 24% (144 of 601 patients) given rituximab.

Gazyvaro has also been investigated in a study involving 321 patients with FL in whom treatment with rituximab had either not worked or had stopped working. Patients treated with Gazyvaro and bendamustine lived longer without their disease getting worse than patients treated with bendamustine alone (29.2 months on average versus 13.7 months).

## What are the risks associated with Gazyvaro?

The most common side effects with Gazyvaro (which may affect more than 1 in 10 people) are upper respiratory infections (such as throat and nose infections), pneumonia (lung infection), urinary tract infections, inflammation in the nose and throat, sinusitis (inflammation of the sinuses), shingles, coughs, diarrhoea, constipation, joint and back pain, pain in arms and legs, headache, insomnia, hair loss, itching, fever, weakness, tiredness, neutropenia and leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts) and reactions related to the infusion (which may include vomiting, dizziness, breathing difficulties, flushing, changes in blood pressure and rapid heart rate). For the full list of side effects and restrictions of Gazyvaro, see the package leaflet.

## Why is Gazyvaro authorised in the EU?

The European Medicines Agency decided that Gazyvaro's benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that the benefit of Gazyvaro in prolonging the survival of CLL and FL patients before their disease worsened was clearly demonstrated. The pattern of side effects was considered acceptable in the light of the medicine's benefit.

## What measures are being taken to ensure the safe and effective use of Gazyvaro?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Gazyvaro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Gazyvaro are continuously monitored. Side effects reported with Gazyvaro are carefully evaluated and any necessary action taken to protect patients.

## Other information about Gazyvaro

Gazyvaro received a marketing authorisation valid throughout the EU on 23 July 2014.

Gazyvaro : EPAR - Summary for the public

Reference Number: EMA/141936/2020

English (EN) (139.13 KB - PDF)

**First published:** 20/08/2014

**Last updated:** 19/05/2020

[View](/en/documents/overview/gazyvaro-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-220)

български (BG) (161.63 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/bg/documents/overview/gazyvaro-epar-summary-public_bg.pdf)

español (ES) (137.98 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/es/documents/overview/gazyvaro-epar-summary-public_es.pdf)

čeština (CS) (160.9 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/cs/documents/overview/gazyvaro-epar-summary-public_cs.pdf)

dansk (DA) (137.54 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/da/documents/overview/gazyvaro-epar-summary-public_da.pdf)

Deutsch (DE) (141.39 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/de/documents/overview/gazyvaro-epar-summary-public_de.pdf)

eesti keel (ET) (126.82 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/et/documents/overview/gazyvaro-epar-summary-public_et.pdf)

ελληνικά (EL) (160.62 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/el/documents/overview/gazyvaro-epar-summary-public_el.pdf)

français (FR) (139.58 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/fr/documents/overview/gazyvaro-epar-summary-public_fr.pdf)

hrvatski (HR) (160.45 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/hr/documents/overview/gazyvaro-epar-summary-public_hr.pdf)

italiano (IT) (137.16 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/it/documents/overview/gazyvaro-epar-summary-public_it.pdf)

latviešu valoda (LV) (169.31 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/lv/documents/overview/gazyvaro-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (160.92 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/lt/documents/overview/gazyvaro-epar-summary-public_lt.pdf)

magyar (HU) (161.53 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/hu/documents/overview/gazyvaro-epar-summary-public_hu.pdf)

Malti (MT) (161.4 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/mt/documents/overview/gazyvaro-epar-summary-public_mt.pdf)

Nederlands (NL) (138.19 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/nl/documents/overview/gazyvaro-epar-summary-public_nl.pdf)

polski (PL) (163.4 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/pl/documents/overview/gazyvaro-epar-summary-public_pl.pdf)

português (PT) (139.52 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/pt/documents/overview/gazyvaro-epar-summary-public_pt.pdf)

română (RO) (160.09 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/ro/documents/overview/gazyvaro-epar-summary-public_ro.pdf)

slovenčina (SK) (162.12 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/sk/documents/overview/gazyvaro-epar-summary-public_sk.pdf)

slovenščina (SL) (158.68 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/sl/documents/overview/gazyvaro-epar-summary-public_sl.pdf)

Suomi (FI) (136.08 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/fi/documents/overview/gazyvaro-epar-summary-public_fi.pdf)

svenska (SV) (136.69 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

19/05/2020

[View](/sv/documents/overview/gazyvaro-epar-summary-public_sv.pdf)

Gazyvaro : EPAR - Risk management plan

English (EN) (1.79 MB - PDF)

**First published:** 20/08/2014

**Last updated:** 04/09/2025

[View](/en/documents/rmp/gazyvaro-epar-risk-management-plan_en.pdf)

## Product information

Gazyvaro : EPAR - Product Information

English (EN) (1.1 MB - PDF)

**First published:** 20/08/2014

**Last updated:** 08/10/2025

[View](/en/documents/product-information/gazyvaro-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-701)

български (BG) (1.55 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/bg/documents/product-information/gazyvaro-epar-product-information_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/es/documents/product-information/gazyvaro-epar-product-information_es.pdf)

čeština (CS) (1.06 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/cs/documents/product-information/gazyvaro-epar-product-information_cs.pdf)

dansk (DA) (819.38 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/da/documents/product-information/gazyvaro-epar-product-information_da.pdf)

Deutsch (DE) (1.93 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/de/documents/product-information/gazyvaro-epar-product-information_de.pdf)

eesti keel (ET) (956.31 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/et/documents/product-information/gazyvaro-epar-product-information_et.pdf)

ελληνικά (EL) (941.75 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/el/documents/product-information/gazyvaro-epar-product-information_el.pdf)

français (FR) (1.01 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/fr/documents/product-information/gazyvaro-epar-product-information_fr.pdf)

hrvatski (HR) (1.11 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/hr/documents/product-information/gazyvaro-epar-product-information_hr.pdf)

íslenska (IS) (981.12 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/is/documents/product-information/gazyvaro-epar-product-information_is.pdf)

italiano (IT) (866.94 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/it/documents/product-information/gazyvaro-epar-product-information_it.pdf)

latviešu valoda (LV) (1.15 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/lv/documents/product-information/gazyvaro-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/lt/documents/product-information/gazyvaro-epar-product-information_lt.pdf)

magyar (HU) (945.5 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/hu/documents/product-information/gazyvaro-epar-product-information_hu.pdf)

Malti (MT) (1.06 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/mt/documents/product-information/gazyvaro-epar-product-information_mt.pdf)

Nederlands (NL) (888.28 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/nl/documents/product-information/gazyvaro-epar-product-information_nl.pdf)

norsk (NO) (834.25 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/no/documents/product-information/gazyvaro-epar-product-information_no.pdf)

polski (PL) (1.1 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/pl/documents/product-information/gazyvaro-epar-product-information_pl.pdf)

português (PT) (847.39 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/pt/documents/product-information/gazyvaro-epar-product-information_pt.pdf)

română (RO) (947.14 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/ro/documents/product-information/gazyvaro-epar-product-information_ro.pdf)

slovenčina (SK) (1.06 MB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/sk/documents/product-information/gazyvaro-epar-product-information_sk.pdf)

slovenščina (SL) (970.52 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/sl/documents/product-information/gazyvaro-epar-product-information_sl.pdf)

Suomi (FI) (909.71 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/fi/documents/product-information/gazyvaro-epar-product-information_fi.pdf)

svenska (SV) (874.99 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

08/10/2025

[View](/sv/documents/product-information/gazyvaro-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000257509 22/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Gazyvaro : EPAR - All Authorised presentations

English (EN) (17.37 KB - PDF)

**First published:** 20/08/2014

**Last updated:** 20/08/2014

[View](/en/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-269)

български (BG) (39.55 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/bg/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.39 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/es/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.34 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/cs/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.27 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/da/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.87 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/de/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.67 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/et/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.17 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/el/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_el.pdf)

français (FR) (23.55 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/fr/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (18.14 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/is/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.2 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/it/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (34.25 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/lv/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.37 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/lt/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.63 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/hu/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.55 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/mt/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.2 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/nl/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.53 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/no/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.29 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/pl/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.35 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/pt/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_pt.pdf)

română (RO) (40 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/ro/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.97 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/sk/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.08 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/sl/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.26 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/fi/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.34 KB - PDF)

**First published:**

20/08/2014

**Last updated:**

20/08/2014

[View](/sv/documents/all-authorised-presentations/gazyvaro-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Gazyvaro Active substance obinutuzumab International non-proprietary name (INN) or common name obinutuzumab Therapeutic area (MeSH) Leukemia, Lymphocytic, Chronic, B-Cell Anatomical therapeutic chemical (ATC) code L01XC15

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Chronic Lymphocytic Leukaemia (CLL)

Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).

Follicular Lymphoma (FL)

Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

## Authorisation details

EMA product number EMEA/H/C/002799

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 21/05/2014 Marketing authorisation issued 22/07/2014 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Gazyvaro : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.67 KB - PDF)

**First published:** 08/10/2025

[View](/en/documents/procedural-steps-after/gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Gazyvaro : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (258.36 KB - PDF)

**First published:** 17/08/2015

**Last updated:** 08/10/2025

[View](/en/documents/procedural-steps-after/gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Gazyvaro-H-C-PSUSA-00010279-202310 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/449468/2024

English (EN) (109.31 KB - PDF)

**First published:** 23/10/2024

[View](/en/documents/scientific-conclusion/gazyvaro-h-c-psusa-00010279-202310-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Gazyvaro-H-C-2799-II-16: EPAR - Assessment Report - Variation

Reference Number: EMA/538285/2017

English (EN) (3.74 MB - PDF)

**First published:** 29/11/2017

**Last updated:** 29/11/2017

[View](/en/documents/variation-report/gazyvaro-h-c-2799-ii-16-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Gazyvaro (II-16)

Reference Number: EMA/CHMP/296989/2017

English (EN) (68.86 KB - PDF)

**First published:** 21/07/2017

**Last updated:** 21/07/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gazyvaro-ii-16_en.pdf)

Gazyvaro-H-C-2799-II-0007 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/345935/2016

English (EN) (5.78 MB - PDF)

**First published:** 28/07/2016

**Last updated:** 28/07/2016

[View](/en/documents/variation-report/gazyvaro-h-c-2799-ii-0007-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Gazyvaro

Adopted

Reference Number: EMA/CHMP/265542/2016

English (EN) (68.2 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 29/04/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gazyvaro_en.pdf)

## Initial marketing authorisation documents

Gazyvaro : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/231450/2014

English (EN) (3.4 MB - PDF)

**First published:** 20/08/2014

**Last updated:** 20/08/2014

[View](/en/documents/assessment-report/gazyvaro-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Gazyvaro

Adopted

Reference Number: EMA/CHMP/280012/2014

English (EN) (67.08 KB - PDF)

**First published:** 23/05/2014

**Last updated:** 23/05/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-gazyvaro_en.pdf)

#### News on Gazyvaro

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025) 17/10/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

[New treatment for rare white blood cell cancer](/en/news/new-treatment-rare-white-blood-cell-cancer) 29/04/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-april-2016) 29/04/2016

[European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014](/en/news/european-medicines-agency-recommends-39-medicines-human-use-marketing-authorisation-first-half-2014) 10/07/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-may-2014) 23/05/2014

[European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukaemia](/en/news/european-medicines-agency-recommends-approval-gazyvaro-chronic-lymphocytic-leukaemia) 23/05/2014

#### Related content

- This product originally had an orphan designation for [treatment of chronic lymphocytic leukaemia](/en/medicines/human/orphan-designations/eu-3-12-1054) , granted on 10 October 2012. This designation was withdrawn from the Community register of orphan medicinal products in July 2024 at the end of the 10-year period of market exclusivity.
- This product originally had an orphan designation for [treatment of follicular lymphoma](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1504) , granted on 19 June 2015. This designation was withdrawn from the Community register of orphan medicinal products in October 2025 upon request of the marketing authorisation holder.
- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC002799II0007) (variation II/0007)

#### More information on Gazyvaro

- [EMEA-001207-PIP01-11-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001207-pip01-11-m01)
- [EMEA-001207-PIP03-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001207-pip03-20)
- [EMEA-001207-PIP02-19-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001207-pip02-19-m01)
- [Gazyvaro - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/gazyvaro)
- [EMEA-001207-PIP06-22 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001207-pip06-22)
- [EMEA-001207-PIP05-22 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001207-pip05-22)
- [Gazyvaro - opinion on variation to marketing authorisation](/en/medicines/human/variation/gazyvaro-0)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/11/2025

## Share this page

[Back to top](#main-content)